Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for
patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides …

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all
solid tumors, and thus new treatment strategies are urgently needed. Here, we report that …

Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West,
has undergone a revolution in the past few years with the development of agents that target …

Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …

Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and
functions as an important regulator of cell proliferation and cell survival in various B cell …